Phase 2 N=122 Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: 2-Year Progression-Free Survival — 71 Percentage of Participants (%)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
Cocaine Use Disorders
Primary: Cocaine Craving Scale — 4.33; 3.13 Units on a scale
Phase 2 N=30 Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Lymphoma
Primary: Overall Response Rate (Complete and Partial Response) — 46 percentage of participants
Phase 2 N=40 Efficacy and Safety of ARTISS for Flap Adherence in Abdominoplasty
Seroma · Hematoma
Primary: Total Drainage Volume Collected Until Drain Removal — 407.45; 595.90 mL
Phase 2 N=141 A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Alzheimer's Disease
Primary: Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events — 30; 39; 28; 17 participants
Phase 2 N=199 Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults
HIV Infections
Primary: Number of Participants Experiencing Any Grade 2 or Higher Clinical Adverse Events (AEs) and Laboratory Abnormalities That Occur From the Initial Injection to Week 41…
Phase 2 N=89 Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
Stable Angina
Primary: Change From Baseline in Total Exercise Time — 8.1; -2.9 seconds
Phase 2 N=24 Vilazodone for Corticosteroid-Induced Memory Impairment
Memory Impairment
Primary: Change From Baseline RAVLT (Rey Auditory Verbal Learning Test) Total T-Score at Day 19 — -3; 0 T-score
Phase 2 N=64 Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients
Patients, Resistant Hypertension
Primary: Number of Participants With Reported Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths — 12; 3; 14; 0 Participants
Phase 2 N=123 Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control
Ovulation Suppression
Primary: Ovulation Suppression in Three Treatment Groups Over 3 Cycles — 36.5; 20.7; 11.5; 36.9 %of cycles with possible ovulation
Phase 2 N=30 Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Adult Ependymoblastoma · Adult Giant Cell Glioblastoma · Adult Glioblastoma
Primary: Dose-limiting Toxicity — 0; 0; 0 Participants
Phase 2 N=894 Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.
Malaria
Primary: Frequency of First Case of Malaria Meeting the Primary Case Definition — 244.77; 238.51; 249.23; 242.06 PYAR — p=<0.001
Phase 2 N=53 EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Lymphoma, Mantle Cell · Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months
Phase 2 N=43 E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
Leukemia
Primary: Overall Response — 11 Participants
Phase 2 N=204 Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants